{
  "ticker": "JNJ",
  "target_date": "2025-06-23",
  "actual_date": "2025-06-23",
  "collected_at": "2025-12-08T11:55:29.876889",
  "price": {
    "open": 147.71,
    "high": 149.38,
    "low": 147.71,
    "close": 149.2696533203125,
    "volume": 7397900,
    "change_1d_pct": 1.02,
    "change_7d_pct": -2.54,
    "change_30d_pct": -1.95
  },
  "technicals": {
    "rsi_14": 38.19,
    "sma_20": 151.81,
    "sma_50": 151.02,
    "macd": -0.286,
    "macd_signal": 0.232,
    "macd_histogram": -0.518,
    "bb_upper": 155.85,
    "bb_lower": 147.78,
    "price_vs_sma20_pct": -1.68,
    "price_vs_sma50_pct": -1.16,
    "volume_ratio": 0.92
  },
  "fundamentals": {
    "market_cap": 489038708736,
    "pe_ratio": 19.592665,
    "forward_pe": 19.149055,
    "price_to_book": 6.160804,
    "price_to_sales": 5.307043,
    "profit_margin": 27.26,
    "operating_margin": 30.2,
    "roe": 33.62,
    "roa": 8.26,
    "revenue_growth": 6.8,
    "earnings_growth": 91.0,
    "debt_to_equity": 57.766,
    "current_ratio": 1.074,
    "quick_ratio": 0.711,
    "dividend_yield": 258.0,
    "fifty_two_week_high": 207.81,
    "fifty_two_week_low": 140.68,
    "fifty_day_avg": 193.4922,
    "two_hundred_day_avg": 170.2741,
    "analyst_target": 203.41833,
    "analyst_recommendation": "buy",
    "num_analysts": 24,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -2.32,
    "pct_from_52w_low": 44.28
  },
  "macro": {
    "spy": {
      "price": 598.49,
      "change_1d_pct": 0.99,
      "change_7d_pct": -0.3
    },
    "vix": {
      "level": 19.83,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.32
    },
    "dollar_index": {
      "level": 98.42
    },
    "gold": {
      "price": 3377.7
    },
    "regime": "BEAR_NORMAL"
  },
  "news": [
    {
      "headline": "Compass\u2019s Psychedelic Drug to Treat Depression Meets Goal in Trial",
      "source": "Yahoo",
      "datetime": 1750686712,
      "summary": "(Bloomberg) -- Compass Pathways Plc\u2019s shares plummeted after its psychedelic drug to treat a form of depression disappointed investors in a late-stage trial.Most Read from BloombergBezos Wedding Draws Protests, Soul-Searching Over Tourism in VeniceOne Architect\u2019s Quest to Save Mumbai\u2019s Heritage From",
      "url": "https://finnhub.io/api/news?id=008d12e2bc2a23b4542f3f9707e07b525d075b4874a22a4c0e2b3342a2148f69"
    },
    {
      "headline": "Are You a Value Investor? This 1 Stock Could Be the Perfect Pick",
      "source": "Yahoo",
      "datetime": 1750686003,
      "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
      "url": "https://finnhub.io/api/news?id=dd432191d18d57a5bb987b50e39b7a2ab1ae0e0f6def39e65477ca184aaa5f29"
    },
    {
      "headline": "J&J Adds More Than $15B in Six Months: How to Play JNJ Stock?",
      "source": "Yahoo",
      "datetime": 1750684920,
      "summary": "JNJ stock added $15B in market value in six months as new drug launches offset MedTech and Stelara headwinds.",
      "url": "https://finnhub.io/api/news?id=7ed278cf006eb3e3a9dbfc23c4678d28e3d998b349c14b34995012709b919acc"
    },
    {
      "headline": "J&J's Drugs Get CHMP Recommendations for Blood Cancer Indications",
      "source": "Yahoo",
      "datetime": 1750684500,
      "summary": "JNJ wins CHMP backing for Darzalex and Imbruvica in new blood cancer uses, paving the way for first-in-class approvals.",
      "url": "https://finnhub.io/api/news?id=deb522c5d398a4d0bf4062e39cf09ebf73620c590ff5e87bad6635d38a3478e0"
    },
    {
      "headline": "Johnson & Johnson Launches First and Only Daily Disposable Multifocal Toric Contact Lens - ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM",
      "source": "Yahoo",
      "datetime": 1750680000,
      "summary": "Today, Johnson & Johnson,\u2020 a global leader in eye health, announced the launch of ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM, the first and only daily disposable contact lens for people with both astigmatism and presbyopia.2 This pioneering contact lens provides patients crisp, clear, stable ",
      "url": "https://finnhub.io/api/news?id=b690a656854393314fafcfb30c0b30560cc77821b3a0f9685808c3e10987afa7"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-06-12",
      "description": "xslF345X05/wk-form4_1749760336.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000156/xslF345X05/wk-form4_1749760336.xml"
    },
    {
      "form": "4",
      "date": "2025-06-12",
      "description": "xslF345X05/wk-form4_1749760229.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000154/xslF345X05/wk-form4_1749760229.xml"
    },
    {
      "form": "8-K",
      "date": "2025-06-10",
      "description": "jnj-20250610.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000152/jnj-20250610.htm"
    },
    {
      "form": "13F-HR",
      "date": "2025-05-07",
      "description": "xslForm13F_X02/primary_doc.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000090445425000238/xslForm13F_X02/primary_doc.xml"
    },
    {
      "form": "4",
      "date": "2025-05-05",
      "description": "xslF345X05/wk-form4_1746479407.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000143/xslF345X05/wk-form4_1746479407.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}